In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes

References

• Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012;101:1647–58.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2013;114:525–31.
   PubMed Web of Science ®Google Scholar
• Danaei G, Finucane MM, Lu Y, Singh GM, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.
   PubMed Web of Science ®Google Scholar
• Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 2008;118:181–91.
   PubMed Web of Science ®Google Scholar
• Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22–33.
   PubMed Web of Science ®Google Scholar
• Van Genugten RE, Van Raalte DH, Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Res Clin Pract 2009;86:S26–34.
   PubMedGoogle Scholar
• Morales J, Schneider D. Hypoglycemia. Am J Med 2014;127:S17–24.
   PubMedGoogle Scholar
• Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 2012;34:1892–908.
   PubMed Web of Science ®Google Scholar
• Furman BL. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon 2012;59:464–71.
   PubMed Web of Science ®Google Scholar
• Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77–88.
   PubMed Web of Science ®Google Scholar
• Iltz JL, Baker DE, Setter SM, Campbell RK. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 2006;28:652–65.
   PubMed Web of Science ®Google Scholar
• Kim D, Macconell L, Zhuang DL, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487–93.
   PubMed Web of Science ®Google Scholar
• Kwak HH, Shim WS, Hwang S, et al. Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in zucker diabetic fatty (ZDF) rats. Pharm Res 2009;26:2504–12.
   PubMed Web of Science ®Google Scholar
• Liu B, Dong QG, Wang MS, Shi L, et al. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres. Chem Pharm Bull 2010;58:1474–9.
   PubMed Web of Science ®Google Scholar
• Millotti G, Vetter A, Leithner K, et al. Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm 2014;40:1677–82.
   PubMed Web of Science ®Google Scholar
• Idris I. Bydureon, granted marketing authorization by the European commission. Diabetes Obesity Metab 2011;13:866–8.
   Web of Science ®Google Scholar
• Idris I. FDA approved the once weekly glucagon like peptide-1, Bydureon. Diabetes Obesity Metab 2012;14:479–80.
   Web of Science ®Google Scholar
• Deyoung MB, Macconell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011;13:1145–54.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Chen S. Polymeric-based particulate systems for delivery of therapeutic proteins. Pharm Dev Technol 2015. [Epub ahead of print]. DOI: 10.3109/10837450.2014.999785.
   PubMed Web of Science ®Google Scholar
• Akash MSH, Rehman K, Chen S. Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins. Polym Rev 2015;55:371–406.
   Web of Science ®Google Scholar
• Yu L, Ding J. Injectable hydrogels as unique biomedical materials. Chem Soc Rev 2008;37:1473–81.
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang H, Ding J. A subtle end group effect on macroscopic physical gelation of triblock copolymer aqueous solutions. Angew Chem Int Ed 2006;45:2232–5.
   PubMed Web of Science ®Google Scholar
• Bender J, Michaelis W, Schubert R. Morphological and thermal properties of vesicular phospholipid gels studied by DSC, rheometry and electron microscopy. J Therm Anal Calorim 2002;68:603–12.
   Web of Science ®Google Scholar
• Brandl M. Vesicular phospholipid gels: a technology platform. J Liposome Res 2007;17:15–26.
   PubMed Web of Science ®Google Scholar
• Nieh MP, Katsaras J, Qi X. Controlled release mechanisms of spontaneously forming unilamellar vesicles. Biochim Biophys Acta 2008;1778:1467–71.
   PubMed Web of Science ®Google Scholar
• Tardi C, Drechsler M, Bauer KH, Brandl M. Steam sterilisation of vesicular phospholipid gels. Int J Pharm 2001;217:161–72.
   PubMed Web of Science ®Google Scholar
• Brandl M, Drechsler M, Bachmann D, et al. Preparation and characterization of semi-solid phospholipid dispersions and dilutions thereof. Int J Pharm 1998;170:187–99.
   Web of Science ®Google Scholar
• Farkas E, Schubert R, Zelk R. Effect of beta-sitosterol on the characteristics of vesicular gels containing chlorhexidine. Int J Pharm 2004;278:63–70.
   PubMed Web of Science ®Google Scholar
• Ruiz MS, Clares MA, Morales B, et al. Vesicular lipidic systems, liposomes, PLO, and liposomes-PLO: characterization by electronic transmission microscopy. Drug Dev Ind Pharm 2008;34:1269–76.
   PubMed Web of Science ®Google Scholar
• Grohganz H, Tho I, Brandl M. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix. Eur J Pharm Biopharm 2005;59:439–48.
   PubMed Web of Science ®Google Scholar
• Ning M, Guo Y, Pan H, et al. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm 2005;31:375–83.
   PubMed Web of Science ®Google Scholar
• Tian W, Schulze S, Brandl M, Winter G. Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: development and in vitro evaluation. J Control Release 2010;142:319–25.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Rawat M, Rawat A, et al. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon α. Drug Dev Ind Pharm 2006;32:699–707.
   PubMed Web of Science ®Google Scholar
• Reed M, Meszaros K, Entes L, et al. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metab Clin Exp 2000;49:1390–4.
   PubMed Web of Science ®Google Scholar
• Kaiser N, Kimpfler A, Massing U, et al. 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int J Pharm 2003;256:123–31.
   PubMed Web of Science ®Google Scholar
• Qi N, Cai CF, Zhang W, et al. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma. Int J Pharm 2014;472:48–55.
   PubMed Web of Science ®Google Scholar
• Yuksel N, Kanık AE, Baykara T. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and -independent methods. Int J Pharm 2000;209:57–67.
   PubMed Web of Science ®Google Scholar
• Tardi C, Brandl M, Schubert R. Erosion and controlled release properties of semisolid vesicular phospholipid dispersions. J Control Release 1998;55:261–70.
   PubMed Web of Science ®Google Scholar
• Akash MS, Rehman K, Chen S. An overview of valuable scientific models for diabetes mellitus. Curr Diabetes Rev 2013;9:286–93.
   PubMedGoogle Scholar
• Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007;125:451.
   PubMed Web of Science ®Google Scholar